immunotherapy

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY®BiTco…

16 hours ago

BreakBio, the Third Player in Personalized Drugs, Enters the Clinic

MIAMI, Aug. 24, 2026 /PRNewswire/ -- BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top…

1 week ago

Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program

CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased…

2 weeks ago

Bioz and InvivoGen Elevate Scientific Discovery with an Expanded Digital Research Experience

PALO ALTO, CA / ACCESS Newswire / August 19, 2026 / Bioz, Inc., the scientific marketing platform that transforms peer-reviewed…

2 weeks ago

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing…

3 weeks ago

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage…

3 weeks ago

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage…

3 weeks ago

Internationally Recognized Johns Hopkins Oncologist Dr. Stephen J. Noga Joins Immunocine as Chief Medical Officer

Veteran Physician-Scientist and Cellular Therapy Expert to Help Advance the Future of Personalized Cancer Immunotherapy In this video, Dr. Matt…

3 weeks ago

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson’s Disease Data Readout Targeted for First Half of 2027

New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational…

4 weeks ago

Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy

MELBOURNE, Australia and OXFORD, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying…

1 month ago